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ABSTRACT
Eosinophils are the key effector cells for allergic inflam-
mation. In order to clarify drugs which can regulate
eosinophil function, we investigated the direct effect of
pemirolast potassium (anti-allergic drug) and FK506
(immunosupressant) on eosinophil degranulation and
cytokine production. Eosinophil degranulation induced
by granulocyte-macrophage colony stimulating factor
and/or platelet activating factor was inhibited from
10–4 to 10–6 mol/L pemirolast (inhibitory effect 66 and
33%, respectively) and 10–8 mol/L FK506 (inhibitory
effect 45%). Pemirolast and FK506 also inhibit inter-
leukin (IL)-8 production by eosinophil. Our data suggest
that both pemirolast potassium and FK506 possess
direct regulatory effects on human eosinophils and a
potential to suppress allergic inflammation.
Key words: anti-allergic drug, cytokine, eosinophil,
degranulation.
INTRODUCTION
Recently, the importance of allergic inflammation in the
pathogenesis of asthma has become widely accepted.1
Eosinophils are the key effector cells for allergic inflam-
mation. Factors such as major basic protein (MBP),
eosinophil cationic protein (ECP), and eosinophil derived
neurotoxin (EDN, eosinophil protein · (EPX)), which are
released from eosinophil granules, damage bronchial
epithelial cells, resulting in bronchial hyperreactivity.1–4 In
addition, recent reports have revealed that eosinophils
produce cytokines and play a pivotal role in allergic
inflammation.5–8 When we are able to interrupt this cas-
cade of reaction, the allergic inflammation may be
controlled. Therefore, recent treatments for asthma target
not only the immediate spastic reaction of the bronchus
but also the inflammatory reaction.
Granulocyte-macrophage colony stimulating factor
(GM-CSF) plays an important role not only in the differen-
tiation but also in the activation of eosinophils.1,9,10
GM-CSF is abundant at the site of allergic inflammation11
Granulocyte-macrophage colony stimulating factor gene
transfer in the lungs of normal mice causes accumulation
of inflammatory cells and irreversible bronchial remodel-
ing.12 Platelet activating factor (PAF) is another important
chemical mediator which activates eosinophils as well as
neutrophils.1 Thus, GM-CSF and PAF constitute the inflam-
matory process of asthma. Pemirolast is an anti-allergic
drug which was originally found to inhibit immunogobulin
E (IgE)-mediated release of a chemical mediator from
mast cells.13,14 It has been shown that pemirolast inhibited
eosinophil chemotaxis.15 Although pemirolast inhibits LTD4
release from eosinophils induced by calcium ionophore,16
the effect of pemirolast on eosinophil degranulation by
physiological stimuli such as GM-CSF has not been clari-
fied. Moreover, the effect of pemirolast on cytokine pro-
duction is unknown.
In order to compare the effect of pemirolast, we exami-
ned the effect of FK506, an immunosuppressant which
also inhibits allergic reaction.17 FK506 prominently sup-
presses GM-CSF and IL-3 release from eosinophils18 and
inhibits mast cell degranulation.19 However, the inhibition
of eosinophil degranulation by FK506 has not been fully
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explored. Thus, in this study we investigated the effect of
pemirolast and FK506 on eosinophil degranulation in
conjunction with IL-8 production, which plays a critical
role of accumulation for leukocytes.20–22
METHODS
Eosinophil purification
Whole blood was obtained from patients with moderate
eosinophilia (6–20%), collected in tubes containing EDTA.
Peripheral blood mononuclear cells were separated by
Ficoll-Hypaque centrifugation. The remaining cells were
separated into erythrocytes and granulocytes by 6%
dexran sedimentation. In order to isolate eosinophils, the
granulocyte population was incubated with mouse anti-
human CD16 monoclonal antibodies (Immunotech SA,
Marseille, France). CD16-positive neutrophils were then
depleted using beads coated with a goat antimouse anti-
body (Dynabeads, Dynal AS, Oslo, Norway).8 The purity
of the negatively selected eosinophils was checked by
staining with Diff-Quick (Baxter, Dudigen, Switzerland)
and was greater than 95%.
Human studies committee approval was obtained and
an individual consent form was completed and signed
prior to the period in which we conducted these studies.
Eosinophil stimulation
Polystyrene tissue culture plates with 96 or 48 wells were
coated with 2% human serum albumin (HAS; Sigma
Chemical Co., St Louis, MO, USA), as described by
Horie and Kita.23 For the degranulation assay, eosinophils
(2 · 105 cells/well) in Pipes A buffer were simultaneously
stimulated using recombinant GM-CSF (10 ng/mL; a
donation from Sherring-Plough Brinny Co., NJ, USA) and
PAF (10–6 mol/L; Bachem Fine Chem. AG, Bubendorf,
Switzerland) for 2 h at 37°C in a 5% CO2 incubator.
Following this, the supernatants were harvested. The levels
of ECP and eosinophil protein X (EPX) were assayed using
radioimmunoassay kits (Pharmacia Fine Chemicals,
Division of Pharmacia Biotechnology International AB,
Uppsala, Sweden). For IL-8 production, eosinophils
(1 · 106 cells/well) in 5% fetal calf serum (FCS) in RPMI
1640 were treated with 5 m g/mL of cytochalasin B (Sigma
Chemical Co.) and were simultaneously stimulated by
recombinant 10 ng/mL GM-CSF and 5000 units/mL tumor
necrosis factor (TNF)-a (R&D System Inc., Minneapolis,
MN, USA) for 16 h at 37°C in a 5% CO2 incubator.
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Fig. 1 Eosinophil degranulation induced by granulocyte-
macrophage colony stimulating factor (GM-CSF) and platelet
activating factor (PAF). Highly purified eosinophils were incu-
bated with GM-CSF (10 ng/mL) and PAF (1 m mol) for 2 h. The
data were expressed as mean ± SEM of four different experi-
ments from four different donors.
Fig. 2 The inhibitory effects of pemirolast and FK506 on
eosinophil degranulation induced by platelet activating factor
(PAF) and granulocyte-macrophage colony stimulating factor
(GM-CSF). Eosinophils were preincubated with the indicated
concentration of the drugs for 30 min and then degranulation
was induced as described in the legend to Fig. 1. The amount
of eosinophil protein X (EPX) released was measured using an
RIA kit. The assay was performed in duplicate. This is represen-
tative data; pooled data is shown in Fig. 3.
The supernatants were harvested and the cell pellets
were lysed by freezing and thawing three times and by the
addition of 1% triton X. The IL-8 levels were measured
using an ELISA kit (R&D System Inc.). The detection limit
of this assay was 10 pg/mL. Eosinophil viability did not
significantly change with the addition of pemirolast
potassium and FK506 at the dose we used as assessed by
trypan blue exclusion technique and propium iodine (PI)
staining (data not shown)
RESULTS
Degranulation induced by GM-CSF and PAF
Eosinophils released EPX in response to activation by
GM-CSF (Fig. 1). Platelet activating factor also induced
the release of EPX. When eosinophils were stimulated by
GM-CSF and PAF simultaneously, larger amounts of EPX
were released (P < 0.01, Fig. 1), indicating that a com-
bination of GM-CSF and PAF has a synergistic effect on
PAF-induced degranulation.
Effects of pemirolast and FK506 on eosinophil
degranulation
We next evaluated the inhibitory effect of pemirolast and
FK506 on eosinophil degranulation induced by the
combination of GM-CSF and PAF. Representative data is
shown in Fig. 2. Pemirolast and FK506 inhibited eosino-
phil degranulation dose-dependently (Fig. 2). A summary
of the inhibitory effects of pemirolast on GM-CSF + PAF-
induced EPX release from eosinophils of 12 different
donors is shown in Fig. 3. The mean inhibitory effect of
pemirolast was 66% at 10–4 mol/L (P < 0.01, multiple
comparison using corrected P by Bonferroni), 47% at 10–5
mol/L (P < 0.05), and 33% at 10–6 mol/L (P < 0.05).
FK506 (10–8 mol/L) also significantly inhibited eosinophil
degranulation at 45 ± 4.3% (P < 0.05, n = 8). These
data suggest that pemirolast and FK506 effectively
suppress eosinophil degranulation.
EFFECTS OF PEMIROLAST AND FK506 39
Fig. 3 Percent inhibitory effect of pemirolast and FK506 on
eosinophil degranulation induced by granulocyte-macrophage
colony stimulating factor (GM-CSF) + platelet activating factor
(PAF). Eosinophils were preincubated with the indicated con-
centration of the drugs for 30 min and then degranulation was
induced as described in the legend to Fig. 2. The percentage
inhibitory effect was calculated as EPX released without pemiro-
last or FK506–EPX released with pemirolast or FK506–EPX
released without pemirolast or FK506. The bar indicates the
mean ± SEM of 12 patients for pemirolast and examinations
and 8 patients for FK506.
Fig. 4 Inhibitory effects of pemirolast and FK506 on IL-8
production induced by granulocyte-macrophage colony stimu-
lating factor (GM-CSF) + TNF-a . Eosinophils were preincubated
with various concentrations of pemirolast and FK506 for 30 min,
and were then stimulated with GM-CSF and TNF-a simultane-
ously. After a 16 h stimulation period, the supernatant and the
cells were harvested. The amount of IL-8 content was measured
in the supernatant of 0.5 · 106 lysed eosinophils in 200 m L of
medium by ELISA. The bar indicates the mean of duplicate deter-
minations. Similar results were obtained from seven different
experiments, with summarized data being shown in Fig. 5.
IL-8 production by eosinophils
The effects of the drugs on total IL-8 production from
extracellular and intracellular IL-8 was examined. In Fig. 4,
a representative result was shown. Pemirolast and FK506
inhibited IL-8 production and secretion by eosinophils
dose-dependently. The summary of inhibitory effects is
shown in Fig. 5. The mean inhibitory effect from seven
donors was 50.2% at 10–4 mol/L of pemirolast (P < 0.05,
multiple comparison using corrected P by Bonferroni),
46.4% at 10–5 mol/L of pemirolast (P < 0.05), and
60.9% at 10–7 mol/L of FK506 (P < 0.05) (Fig. 4). Thus,
pemirolast and FK506 inhibit IL-8 production from
eosinophils.
DISCUSSION
The need for anti-allergic drugs that regulate eosinophil
function has been clear since asthma was first considered
to be an inflammatory response of the airway.1 In this
report, we have shown that pemirolast and FK506 can
directly act on eosinophils to suppress degranulation and
cytokine production, which may result in the disruption of
the inflammatory cascade of asthma in vivo.
It has been reported that GM-CSF has a priming effect
for the expression of adhesion molecules on eosinophils
induced by N-formyl-methionyl-leucyl-phenylalanine or
PAF.10 Interleukin-5 has a priming effect for cytokine pro-
duction induced by RANTES or IL-8.24 We showed that
GM-CSF had a synergistic effect on eosinophil degranu-
lation induced by PAF. Such effects of chemical mediators
and cytokines will lead to the activation of cytokine
cascade in asthma. We examined the inhibitory effects of
drugs on degranulation of eosinophils induced by
GM-CSF + PAF. Pemirolast inhibited degranulation of
eosinophils at concentrations as low as 10–6 mol/L. In
humans, the maximum serum concentration at regular
doses of pemirolast has been reported to be 3 · 10–6
mol/L.25 Thus, the inhibitory effect observed in our study
would occur in vivo at clinical dosages.
It has been reported that pemirolast inhibits chemo-
taxis of eosinophils,15 and that pemirolast inhibits LTC4
release from eosinophils.16 However, there are no studies
regarding the effects of pemirolast on cytokine produc-
tion. In this study, we showed that pemirolast suppressed
degranulation and cytokine production. The suppressive
effect on cytokine production was comparable to that of
FK506. These data suggested an in vivo effect of pemiro-
last in allergic inflammatory regulation.
FK506 also directly affected eosinophil degranula-
tion and IL-8 production. Because the suppressive effect
of cytokine production on T cell is prominent,26 we
removed lymphocytes by Ficoll-Hypaque gradient sepa-
ration and by using anti-CD3 monoclonal antibodies
in order to eliminate the effects of FK506 through lym-
phocytes. We achieved contamination by neutrophils
in less than 5% of purified eosinophils, and contami-
nation by lymphocytes below 1% of purified eosinophils.
FK506 also inhibited eosinophil degranulation similar
to pemirolast.
It has been reported that FK506 inhibits mast cell
degranulation as well as cytokine production.19 In regard
to eosinophils, it has been reported that IL-3 and
GM-CSF production induced by Ca ionophore was sup-
pressed by FK506.18 Eosinophils produce a significant
amount of IL-8 by various physiological stimuli.8,27,28
FK506 (10–7 mol/L) exhibit a stronger inhibitory effect
than pemirolast (10–4 mol/L). IL-8 is a pro-inflammatory
cytokine which contributes to inflammation in asthma
sufferers.20,21 Regulating IL-8 production may be a way of
controlling allergic inflammation.
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Fig. 5 Percent inhibitory effects of pemirolast and FK506 on
IL-8 production. Inhibitory effects of pemirolast and FK506 IL-8
production by eosinophils were examined as described in the
legend to Fig. 4. Percent inhibition was calculated as IL-8
production without pemirolast or FK506–IL-8 production with
pemirolast or FK506–IL-8 production without pemirolast or
FK506. The bar represents mean ± SEM of results from seven
different donors.
Recently, the signal transduction pathways of eosino-
phils have been clarified.29–34 L-3, IL-5 and GM-CSF,
which use a common receptor b subunit, induce tyrosine
phosphorylation of lpr/yes-related novel gene (lyn) and
spleen tyrosine kinase (syk) in eosinophils.30 Tyrosine
phosphorylation of lyn and syk plays an essential role in
apoptosis of eosinophils, which has been demonstrated
using antisense oligonucleotides of lyn and syk.31 We
found that tyrosine phosphorylation is required for
eosinophil degranulation induced by PAF and IL-8 pro-
duction induced by GM-CSF + TNF-a (data not shown).
It has been reported that pemirolast inhibits MAP-kinase
activity on human basophilic leukemia cells.35 Further
investigation is needed in order to establish whether
pemirolast inhibits degranulation via suppressive effects
on MAP-kinase.
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